Sorrento Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. The company operates through two segments, Sorrento Therapeutics and Scilex, and utilizes its proprietary G-MAB antibody library to create a diverse array of treatment modalities, including chimeric antigen receptor T-cell therapies, antibody-drug conjugates, and targeted drug delivery systems like Sofusa, which delivers biologics into the lymphatic system. Sorrento's pipeline includes anti-CD38 CAR-T therapy for multiple myeloma and other conditions, as well as resiniferatoxin, a neurotoxin aimed at alleviating pain in late-stage cancer patients and those with osteoarthritis. Additionally, Sorrento is advancing other products such as ZTlido for postherpetic neuralgia and SEMDEXA for sciatica. The company is also involved in collaborative efforts to develop COVID-19 therapeutic candidates, including antibody therapies targeting SARS-CoV-2. Founded in 2006, Sorrento Therapeutics continues to address significant unmet medical needs in various therapeutic areas.
Ancora Medical is a privately held medical technology company focused on developing innovative catheter technology aimed at improving surgical pain management. The company's anchoring catheter and needle combination is designed to administer long-lasting anesthesia during the preoperative, perioperative, and postoperative phases of general and orthopedic surgery. Ancora's technology enhances the precision of nerve localization by utilizing electrical impulses from a nerve stimulator in conjunction with ultrasound visualization. This approach aims to provide healthcare professionals with an effective and affordable solution for managing surgical pain, ultimately improving patient outcomes.
Virex Health is a biotechnology company focused on enhancing public health through innovative diagnostic solutions. It manufactures rapid point-of-care testing kits that utilize a glucometer and a specialized test strip, which allow for affordable and scalable diagnostic services. These kits are designed for a variety of applications, including COVID-19 testing and early cancer detection. By enabling widespread testing in diverse environments such as homes, workplaces, schools, and public spaces, Virex Health aims to improve accessibility to advanced diagnostics and contribute to better health outcomes globally.
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics was founded by Tien Lee in 2017.
ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases.ACEA has expanded drug discovery efforts to encompass development in both targeted and immunotherapy areas. Alongside a robust R&D organization, ACEA has established drug manufacturing and commercial capabilities in China to support its long-term growth. This infrastructure provides ACEA greater control over the drug supply chain to make sure products are delivered to patients on time and at the highest quality. ACEA is well-positioned to deliver on its promise to bring innovative treatments to patients living with life-threatening diseases while creating value for shareholders, employees, and society.
SmartPharm Therapeutics is a development-stage biopharmaceutical company focused on creating non-viral gene therapies for serious and rare diseases. Founded in 2017 and based in Cambridge, Massachusetts, SmartPharm aims to develop a pipeline of gene-encoded therapeutics that allow patients' bodies to produce essential biologics for conditions requiring such treatments, including enzyme replacement and tissue restoration. The company's innovative platform emphasizes minimal immunogenicity, re-dosability for patients, and scalable manufacturing, while also seeking to simplify regulatory processes. By leveraging insights gained from previous gene therapy developments, SmartPharm integrates advanced technologies to produce optimal gene-encoded therapies, thereby enhancing the therapeutic benefits for patients without the complications associated with viral vectors.
Semnur Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the clinical and commercial development of innovative products that meet the needs of pain management practitioners and their patients.
Scilex Holding Co is a pharmaceutical company dedicated to acquiring, developing, and commercializing non-opioid pain management products aimed at treating both acute and chronic pain. The company’s primary commercial product, ZTlido, is a topical lidocaine system designed to alleviate pain associated with postherpetic neuralgia, a nerve pain condition following shingles. Additionally, Scilex is focused on bringing Gloperba, an oral solution used for the prophylactic treatment of painful gout flares in adults, to market. The company is also advancing several product candidates, including SP-102, a viscous gel formulation intended for epidural injections, and SP-103, a Phase 2 candidate designed for pain management. By concentrating on innovative delivery methods and effective treatments, Scilex aims to address the significant need for safer alternatives in pain management.
Globavir, founded in 2011 by Dr. Shalabh Gupta, focuses on developing therapeutics and diagnostics for infectious diseases. The company leverages multiple licenses from Stanford University to advance its research and product development. Globavir acquired BioCycive in 2014, integrating it as a wholly owned subsidiary. This acquisition allowed Globavir to expand its capabilities, leading to a partnership in 2015 with Sorrento Therapeutics to advance BioCycive's lead program. Additionally, in 2016, Globavir collaborated with Bio-Rad to enhance its diagnostic test offerings. The company addresses a range of infectious diseases, including dengue, West Nile, chikungunya, and Ebola, while also extending its research efforts into cancer treatment.
NantiBodyFc
Private Equity Round in 2015
NantiBodyFc operates in the healthcare industry. Founded in 2015, the company is headquartered in Cumming, Georgia, United States.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.